Invesaro

Stocks Comparison

LifeStance Health vs GeneDx: revenue, profit, margins and growth compared

LifeStance Health brought in $1.4B of revenue in fiscal 2025, GeneDx $427.5M in fiscal 2025. Revenue changed by +13.9% at LifeStance Health and +40.0% at GeneDx on the year before, so GeneDx grew faster. LifeStance Health kept 0.7% of its revenue as net profit, GeneDx -4.9%. Free cash flow was $110M at LifeStance Health and $14.3M at GeneDx.

Side by side, latest fiscal year

LFSTWGS
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$1.4B$427.5M
Revenue growth+13.9%+40.0%
Net income$9.7M-$21M
Net margin0.7%-4.9%
Free cash flow$110M$14.3M
Free cash flow margin7.7%3.3%
Earnings per share (diluted)n/a-$0.73
Cash$248.6M$105M
Debt$282.8M$54.5M
Price to earningsn/an/a
Market value$4.5B$2.6B
Dividend yieldn/an/a
Rank by revenue in sector#126 of 523 · Health care#199 of 523 · Health care

Over the years

Revenue
LFST FY2019: $212.5MLFST FY2021: $667.5MLFST FY2022: $859.5MLFST FY2023: $1.1BLFST FY2024: $1.3BLFST FY2025: $1.4BWGS FY2019: $196.2MWGS FY2020: $179.3MWGS FY2021: $212.2MWGS FY2022: $234.7MWGS FY2023: $202.6MWGS FY2024: $305.5MWGS FY2025: $427.5MFY19FY20FY21FY22FY23FY24FY25
LFST $1.4BWGS $427.5M
Net income
LFST FY2019: $5.7MLFST FY2021: -$307.2MLFST FY2022: -$215.6MLFST FY2023: -$186.3MLFST FY2024: -$57.4MLFST FY2025: $9.7MWGS FY2019: -$29.7MWGS FY2020: -$241.3MWGS FY2021: -$245.4MWGS FY2022: -$549MWGS FY2023: -$175.8MWGS FY2024: -$52.3MWGS FY2025: -$21MFY19FY20FY21FY22FY23FY24FY25
LFST $9.7MWGS -$21M
Net margin
LFST FY2019: 2.7%LFST FY2021: -46.0%LFST FY2022: -25.1%LFST FY2023: -17.6%LFST FY2024: -4.6%LFST FY2025: 0.7%WGS FY2019: -15.1%WGS FY2020: -134.6%WGS FY2021: -115.6%WGS FY2022: -233.9%WGS FY2023: -86.8%WGS FY2024: -17.1%WGS FY2025: -4.9%FY19FY20FY21FY22FY23FY24FY25
LFST 0.7%WGS -4.9%
Revenue growth
LFST FY2022: +28.8%LFST FY2023: +22.8%LFST FY2024: +18.5%LFST FY2025: +13.9%WGS FY2020: -8.6%WGS FY2021: +18.3%WGS FY2022: +10.6%WGS FY2023: -13.7%WGS FY2024: +50.8%WGS FY2025: +40.0%FY20FY21FY22FY23FY24FY25
LFST +13.9%WGS +40.0%
Free cash flow
LFST FY2019: $2.7MLFST FY2021: -$85.1MLFST FY2022: -$26.5MLFST FY2023: -$57.4MLFST FY2024: $85.7MLFST FY2025: $110MWGS FY2019: -$30.7MWGS FY2020: -$117.2MWGS FY2021: -$199.8MWGS FY2022: -$326.3MWGS FY2023: -$185.4MWGS FY2024: -$34MWGS FY2025: $14.3MFY19FY20FY21FY22FY23FY24FY25
LFST $110MWGS $14.3M

Fiscal years as each company reports them; the two may end in different months.

Questions about LifeStance Health and GeneDx

Which is bigger by revenue, LifeStance Health or GeneDx?

LifeStance Health is bigger by revenue: $1.4B in fiscal 2025, against $427.5M for GeneDx in fiscal 2025.

Which keeps more of its revenue as profit, LifeStance Health or GeneDx?

LifeStance Health had a net margin of 0.7% in fiscal 2025; GeneDx had -4.9% in fiscal 2025.

Which grew revenue faster, LifeStance Health or GeneDx?

In their latest fiscal years revenue changed by +13.9% at LifeStance Health and +40.0% at GeneDx.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies